Baird Medical Shines at 2025 Microcap Conference: Driving Growth Through Technological Innovation and Strategic Collaborations
Baird Medical (NASDAQ: BDMD), a leader in microwave ablation technology, participated in the 2025 Microcap Conference at the Borgata Hotel in Atlantic City. The event, which attracted over 750 institutional investors and industry experts, served as a platform for the company to showcase its minimally invasive microwave ablation technology and discuss its recent FDA 510(k) clearance for the U.S. market.
During the conference, Baird Medical's leadership team conducted one-on-one meetings with investors to outline U.S. market penetration strategies and engaged in discussions about potential mergers and acquisitions. Chairwoman Haimei Wu emphasized the conference's role in connecting with global investors and identifying collaboration opportunities. The company plans to leverage these insights to advance its global expansion while continuing investments in research and development.
Baird Medical (NASDAQ: BDMD), leader nella tecnologia di ablazione a microonde, ha partecipato alla Microcap Conference 2025 presso il Borgata Hotel di Atlantic City. L'evento, che ha attratto oltre 750 investitori istituzionali e esperti del settore, ha offerto una piattaforma all'azienda per presentare la sua tecnologia di ablazione a microonde minimamente invasiva e discutere il recente nulla osta FDA 510(k) per il mercato degli Stati Uniti.
Durante la conferenza, il team dirigenziale di Baird Medical ha condotto incontri individuali con gli investitori per illustrare le strategie di penetrazione nel mercato statunitense e ha partecipato a discussioni su potenziali fusioni e acquisizioni. La presidente Haimei Wu ha sottolineato il ruolo della conferenza nel connettersi con investitori globali e identificare opportunità di collaborazione. L'azienda intende sfruttare questi approfondimenti per promuovere la propria espansione globale, continuando a investire in ricerca e sviluppo.
Baird Medical (NASDAQ: BDMD), líder en tecnología de ablación por microondas, participó en la Conferencia Microcap 2025 en el Borgata Hotel de Atlantic City. El evento, que atrajo a más de 750 inversores institucionales y expertos de la industria, sirvió como una plataforma para que la empresa mostrara su tecnología de ablación por microondas mínimamente invasiva y discutiera su reciente aprobación de la FDA 510(k) para el mercado estadounidense.
Durante la conferencia, el equipo directivo de Baird Medical llevó a cabo reuniones uno a uno con inversores para detallar las estrategias de penetración en el mercado estadounidense y participó en discusiones sobre posibles fusiones y adquisiciones. La presidenta Haimei Wu enfatizó el papel de la conferencia en la conexión con inversores globales e identificación de oportunidades de colaboración. La empresa planea aprovechar estas ideas para impulsar su expansión global mientras continúa invirtiendo en investigación y desarrollo.
Baird Medical (NASDAQ: BDMD), 마이크로 웨이브 절제 기술의 선두주자, 애틀랜틱 시티의 Borgata 호텔에서 열린 2025 Microcap Conference에 참여했습니다. 750명 이상의 기관 투자자와 산업 전문가를 끌어들인 이번 행사에서, 회사는 최소 침습적인 마이크로 웨이브 절제 기술을 선보이고 미국 시장을 위한 최근 FDA 510(k) 승인을 논의할 기회를 가졌습니다.
컨퍼런스 동안 Baird Medical의 경영진은 투자자들과 일대일 회의를 통해 미국 시장 침투 전략을 설명하고, 잠재적인 인수합병에 대한 논의에 참여했습니다. 의장인 Haimei Wu는 글로벌 투자자와의 연결 및 협력 기회 식별에서 컨퍼런스의 역할을 강조했습니다. 회사는 이러한 인사이트를 활용하여 글로벌 확장을 추진하고 연구개발에 대한 투자를 계속할 계획입니다.
Baird Medical (NASDAQ: BDMD), leader dans la technologie d'ablation par micro-ondes, a participé à la Conférence Microcap 2025 au Borgata Hotel d'Atlantic City. L'événement, qui a attiré plus de 750 investisseurs institutionnels et experts de l'industrie, a servi de plateforme à l'entreprise pour présenter sa technologie d'ablation par micro-ondes peu invasive et discuter de son récent agrément FDA 510(k) pour le marché américain.
Lors de la conférence, l'équipe dirigeante de Baird Medical a mené des réunions en tête-à-tête avec des investisseurs pour exposer les stratégies de pénétration du marché américain et s'est engagée dans des discussions sur de potentielles fusions et acquisitions. La présidente Haimei Wu a souligné le rôle de la conférence dans la connexion avec des investisseurs globaux et l'identification d'opportunités de collaboration. L'entreprise prévoit de tirer parti de ces aperçus pour faire avancer son expansion mondiale tout en continuant à investir dans la recherche et le développement.
Baird Medical (NASDAQ: BDMD), ein führendes Unternehmen im Bereich der Mikrowellenablationstechnologie, nahm an der Microcap Conference 2025 im Borgata Hotel in Atlantic City teil. Die Veranstaltung, die über 750 institutionelle Investoren und Branchenexperten anlockte, diente der Firma als Plattform, um ihre minimalinvasive Mikrowellenablationstechnologie zu präsentieren und ihre kürzliche FDA 510(k) Genehmigung für den US-Markt zu diskutieren.
Während der Konferenz führte das Führungsteam von Baird Medical persönliche Gespräche mit Investoren, um Strategien zur Marktdurchdringung in den USA darzulegen, und beteiligte sich an Diskussionen über potenzielle Fusionen und Akquisitionen. Vorsitzende Haimei Wu betonte die Rolle der Konferenz, um mit globalen Investoren in Kontakt zu treten und Kooperationsmöglichkeiten zu identifizieren. Das Unternehmen plant, diese Erkenntnisse zu nutzen, um seine globale Expansion voranzutreiben und gleichzeitig in Forschung und Entwicklung zu investieren.
- Recent FDA 510(k) clearance obtained for U.S. market entry
- Active discussions with potential M&A partners for strategic growth
- Strong positioning in microwave ablation technology sector
- None.
As the largest independent microcap conference in the
At the conference, Baird Medical demonstrated its cutting-edge minimally invasive microwave ablation technology, drawing significant attention from attendees and underscoring the Company's leadership in research and development. Additionally, the Company shared its global expansion strategy following the recent FDA 510(k) clearance for the U.S. market.
During the event, Baird Medical's leadership team held numerous one-on-one meetings with investors, detailing the Company's growth plans for the U.S. market, including market penetration strategies and product promotion initiatives. The team also engaged in extensive discussions with several industry players regarding potential mergers and acquisitions. These conversations focused on resource integration, technological synergies, and market collaboration, aiming to identify strategic opportunities that could drive mutual growth and advance the microwave ablation industry.
"The Microcap Conference provided us with a valuable opportunity to connect with global investors and industry partners," said Haimei Wu, Chairwoman of Baird Medical. "We not only showcased our technological expertise but also gained clarity on future collaboration opportunities. We look forward to accelerating our global market expansion and achieving efficient resource integration through strategic mergers and acquisitions."
Moving forward, Baird Medical plans to leverage the insights and partnerships gained from the conference to further its mission of improving patient outcomes worldwide through innovative technologies. The Company will continue to invest in research and development to enhance product quality and performance while actively exploring merger and acquisition opportunities to consolidate its global leadership in the microwave ablation field. By integrating complementary resources, Baird Medical aims to deliver superior medical solutions to patients around the world.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.
These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.
Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-shines-at-2025-microcap-conference-driving-growth-through-technological-innovation-and-strategic-collaborations-302363962.html
SOURCE BDMD
FAQ
What was the significance of Baird Medical's (BDMD) participation in the 2025 Microcap Conference?
What recent regulatory approval did Baird Medical (BDMD) receive for the U.S. market?
What strategic opportunities is Baird Medical (BDMD) pursuing after the 2025 Microcap Conference?
How does Baird Medical (BDMD) plan to expand in the U.S. market?
